Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315483 | 1.00 | AKR1B1 (0.56) | AKR1B1SLC28A3TDP1TMPRSS2USP2 | |
| SCHEMBL13456979 | 1.00 | AKR1B1 (0.56) | AKR1B1SLC28A3TDP1TMPRSS2USP2 | |
| SCHEMBL4620889 | 1.00 | AKR1B1 (0.56) | AKR1B1SLC28A3TDP1TMPRSS2USP2 | |
| SCHEMBL22504483 | 1.00 | AKR1B1 (0.56) | AKR1B1SLC28A3TDP1TMPRSS2USP2 | |
| SCHEMBL1263104 | 1.00 | AKR1B1 (0.56) | AKR1B1SLC28A3TDP1TMPRSS2USP2 | |
| SCHEMBL16906157 | 1.00 | AKR1B1 (0.56) | AKR1B1SLC28A3TDP1TMPRSS2USP2 | |
| SCHEMBL11986810 | 1.00 | AKR1B1 (0.56) | AKR1B1SLC28A3TDP1TMPRSS2USP2 | |
| SCHEMBL5664342 | 0.89 | EPHX2 (0.55) | AKR1B1SLC28A3TMPRSS2USP2PDE5A | |
| SCHEMBL11986813 | 0.89 | SLC28A3 (0.50) | AKR1B1SLC28A3TDP1MAPK1PTPN1 | |
| SCHEMBL28793347 | 0.89 | TMPRSS2 (0.52) | AKR1B1TMPRSS2USP2PDE5ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1808169-B1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH INC (US) | 2012-05-30 | — | — | EP | claimed |
| JP-4370072-B2 | — | — | 2009-11-25 | — | — | JP | claimed |
| EP-1808169-A2 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | Proteotech Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| CN-1668311-A | Method and composition for treating diabetes | UNIV OHIO (US) | 2005-09-14 | — | — | CN | claimed |
| JP-2003532634-A | — | — | 2003-11-05 | — | — | JP | claimed |
| EP-1244435-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES | Proteotech Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| US-6159585-A | Security paper | GEORGIA-PACIFIC CORPORATION (US) | 2000-12-12 | — | — | US | claimed |
| WO-1998041688-A1 | SECURITY PAPER | GEORGIA-PACIFIC CORPORATION, INC. (US) | 1998-09-24 | — | — | WO | claimed |
| EP-2968272-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | Alevere Medical Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150197536-A1 | COMPOUNDS REDUCING THE PRODUCTION OF SORBITOL IN THE EYE AND METHODS OF USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-16 | — | — | US | disclosed |
| WO-2014143125-A1 | USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING | ALEVERE MEDICAL CORPORATION (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-1998041688-A1 | SECURITY PAPER | GEORGIA-PACIFIC CORPORATION, INC. (US) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197536-A1 | COMPOUNDS REDUCING THE PRODUCTION OF SORBITOL IN THE EYE AND METHODS OF USING THE SAME | SORD, ALDOA, SLC2A1 | AKR1B1 107/4885SLC28A3 950/4885TDP1 4393/4885 |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | AKR1B1 1824/4885SLC28A3 3177/4885TDP1 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.